- The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of...
Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductionsSubstantial improvements in insulin resistance were also...
Clinicians’ Choice Fat Burner for Women, PhenQ: Clinically Endorsed by 800 Healthcare Professionals Launched Over the Counter in the USA and Worldwide.
Clinicians’ Choice Fat Burner for Women, PhenQ: Clinically Endorsed by 800 Healthcare Professionals Launched Over the Counter in the USA and Worldwide.
Exhale Wellness launches its new line of Delta 9 Gummies - Bottle Caps. Learn about the product - ingredients, flavors, lab tests, etc. Read User Reviews
Exhale Wellness launches its new line of Delta 9 Gummies - Bottle Caps. Learn about the product - ingredients, flavors, lab tests, etc. Read User Reviews
While competitors push high-THC options, Area 52’s Delta 8 Gummies lead with a balanced, clear-headed experience—now joined by UFO MAX and UFO in the top 3
While competitors push high-THC options, Area 52’s Delta 8 Gummies lead with a balanced, clear-headed experience—now joined by UFO MAX and UFO in the top 3
Burlingame, CA, July 02, 2025 (GLOBE NEWSWIRE) -- The global automotive bumper market is estimated to be valued at USD 21.27 Bn in 2025 and is expected to reach USD 28.37 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.2% from 2025 to 2032. The growth of the automotive bumper market is driven by the increasing global production of automobiles. Rising concerns over passenger safety are further fueling demand for automotive bumpers. Additionally, advancements in bumper design and materials aimed at improving aesthetics and enhancing damage resistance during low-speed collisions are expected to support market expansion. The rising sales of electric vehicles, along with a focus on reducing vehicle body weight, are also set to create new opportunities for lightweight bumpers in the market.
Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...
Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...
Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...
Phase 2 data highlights best-in-class potential of dual GLP-1R/GIPR agonist BGM0504 for weight management and metabolic risk reduction in individuals with type 2 diabetes...